SSH.COM
7.6.2019 09:02:04 CEST | Business Wire | Press release
SSH.COM today announced that their access management gateway solution, PrivX , is now available for free in limited host environments to give IT and software teams all over the world the opportunity to enjoy the benefits of lean, scalable and automated access management to hybrid and multi-cloud (AWS, GCP, Azure, OpenStack) servers and applications.
Cloudification has changed the face of software development and deployment and IT management; modern techniques in software delivery require that trusted access management is in lockstep with development cycles, such as those used in the Continuous Integration/Continuous Delivery (CI/CD) models, while servers are located across on-prem, virtual private cloud (VPC) and multi-cloud environments. Extra steps, bottlenecks and manual processes simply don’t fit into that equation; it’s all about elasticity and automation.
SSH.COM’s Chief Customer Officer, Sami Ahvenniemi: “Spurred on by the shift to the cloud, we have identified that many our customers are looking for the following types of solutions:
- Modern and lean administrative access management tools
- Zero Trust solutions that manage access to critical assets, inside the perimeter
- Automated, scalable alternatives to in-house jump hosts and VPNs
- Centralized 3rd party access controls with monitoring and session recording
The focus is now on the entire access lifecycle of employees, including new hires, people moving around the organization, and people leaving the company. For example, developers, admins and external contractors are all needed - often temporarily - for various tasks with different levels of privilege, all within the critical IT infrastructure. Further, companies and teams often want to start small and scale IT management tools as needed, without taking on the burden of massive IT projects or turning their infrastructure into a hard-to-maintain and complex system. With PrivX, they get an access management solution that deploys in a matter of days, practically updates itself, provides monitoring of access traffic and delivers a simple user experience.”
SSH.COM’s PrivX offers just-in-time role-based access controls to multi-cloud and on-premises resources in development and production environments. Access authorization is never permanent but is based on short-lived certificates that expire within a few minutes of establishing the RDP/SSH connection. PrviX is an agentless and credentialess solution that integrates with existing identity access management (IAM) and directory service (AD/LDAP) tools as well as cloud-hosted servers and applications, including auto-discovery of cloud hosts.
SSH.COM is now making PrivX available free of charge online . Companies can start small and scale with PrivX as their business needs grow.
Mr. Ahvenniemi continued, “Cloud and hybrid environments require technological solutions that emphasize speed and agility over legacy products that are patched up to fit the needs of the cloud. That is why we built PrivX.”
Learn more about PrivX:
- Visit our PrivX product page .
- Download the PrivX datasheet .
- PrivX is reviewed in Kuppinger Cole’s Executive View Report .
- Read about PrivX and its ephemeral certificate-based authentication in our white paper .
About SSH.COM
SSH.COM helps organizations access, secure and control their digital core – their critical data, applications and services. We have over 3,000 customers around the world, including 40 percent of Fortune 500 companies, many of the world’s largest financial institutions, and major organizations in all verticals. We are committed to helping our customers thrive in the cloud era with solutions that offer secure access with zero inertia, zero friction and zero credentials risk. SSH.COM sells online; through offices in North America, Europe and Asia; and through a global network of certified partners. The company’s shares (SSH1V) are quoted on the NASDAQ Helsinki. For more information, visit www.ssh.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005053/en/
Contact:
SSH.COM Contact : Simo Karkkulainen SSH.COM +358 40 738 9406 simo.karkkulainen@ssh.com SSH.COM Agency Contact : Hanah Johnson March Communications +1 617-960-8892 ssh@marchcomms.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
Ant International Launches Industry's First Full-Stack AI-Native Solutions for Payment, Account, FX, Treasury and Growth Operations for Global Businesses18.9.2026 08:53:00 CEST | Press release
In its largest-ever product upgrade, the company unveils an industry-first AI-native, end-to-end full financial stack with close to 100 key products across 4 business pillars.Built on newly upgraded Antom 3-in-1 Transformer, our payment foundation model, and FalconTST, our AI FX & liquidity forecast model.Underpinned by an agent-ready, 2-layered trust and security framework, and a governance-by-design approach that keeps us aligned with evolving compliance and regulatory environments.Autopilots for payment, account and treasury management embedded in the end-to-end financial stack to manage the five main workstreams in natural-language interaction.Introduces agent-native solutions including world's first Account for Agent (AFA) for businesses.89.5% of clients of our main merchant payment service already deployed our FinAI solutions in past 12 months. 81.4% of payment tasks were completed with AI help. In an industry first, Ant International launched a full stack of AI-native solutions
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems18.9.2026 07:00:00 CEST | Press release
2026 Awardees are Corus International,Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh)Commitment of USD 22.2 Million Increases Takeda’s Total Global CSR Program Contributions to USD 260.9 Million Across 42 Diverse Collaborations Worldwide, With 20 Currently Ongoing in 42 Countries Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting global aid priorities continue to challenge healthcare access, Takeda is advancing its 2026 collaborations with the goal of expanding equitable access, strengthening health sy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom